Emergent Health Corp. Announces Patent Approval For Adult Stem Cell Product


KING OF PRUSSIA, Pa., March 9, 2009 (GLOBE NEWSWIRE) -- Emergent Health Corp. (Pink Sheets:EMGE), a diversified holding corporation focused on the biotechnology sector, announces the Company has received approval from the U.S. Patent and Trademark office for their adult stem cell nutrition product Neuvitale(tm) Life Support.

An Emergent spokesperson commented, "The Company is pleased to announce a license to market a formulation with ability to increase adult stem cells naturally from a person's own bone marrow has been allowed by the U.S. Patent and Trademark office. Now that this patent has been allowed, Emergent will seek further corporate and joint venture opportunities with firms capable of assisting entry into this untapped estimated Multi-Billion dollar market currently dominated by drugs with high costs."

By 2004 the world market for Colony Stimulating Factor products, Neulasta(r) and Neupogen(r) marketed by Amgen was valued at $3.6 billion, a growth of 11% over 2003. That market has grown at an average annual growth rate of 16% over the previous 5 years. This is cited only as a market size barometer.

In addition to this product, the Company is actively exploring additional investment projects involved in the adult, umbilical cord, and embryonic stem cell sector to add to its growing portfolio of biotechnology ventures.

The Company is also pleased to announce that Emergent Health Corp. has been added as a new component to the Ludlow Biotech Stock Index. A full research outline on the Company can be found at http://www.ludlowcapital.com/reports/bio/emge.html

About Emergent Health Corp

Emergent Health Corp., a diversified biotechnology venture firm, is focused on the health and wellness industry. Emergent believes it is positioned a leader in the field of Regenerative Medicine defined by the National Institute of Health using nutritionally designed products. Emergent products are not drugs and do not claim to diagnose, prevent or treat disease. Emergent is headquartered in King of Prussia, PA; www.emergenthealth.com. The Company is also being featured by Stock Theatre.com at http://stocktheater.com/index.php?page=000EMGE

This press release contains certain "forward-looking" statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.

This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.


            

Contact Data